Clinical Trial Update: Somatostatin, Octreotide, Pentoxyfilline in the Prevention of Post-ERCP Pancreatitis and Molecular Markers

View source ↗

Summary

A completed clinical trial evaluated somatostatin, octreotide, and pentoxifylline for preventing post-ERCP pancreatitis and assessed molecular markers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-ercp Pancreatitis

Drugs mentioned

• OCTREOTIDE (OCTREOTIDE ACETATE)
• Pentoxifylline (pentoxifylline)
• Somatostatin (somatostatin)

Snippet

Sponsor: University of Ioannina | Conditions: Post-ERCP Acute Pancreatitis | Status: COMPLETED